PHIO RSI Chart
Last 7 days
-1.4%
Last 30 days
1.5%
Last 90 days
17.0%
Trailing 12 Months
-82.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2019 | 136.0K | 78.0K | 21.0K | 21.0K |
2018 | 45.8K | 76.5K | 107.3K | 138.0K |
2017 | 0 | 0 | 0 | 15.0K |
2016 | 10.0K | 19.0K | 19.0K | 19.0K |
2015 | 76.0K | 64.0K | 48.0K | 34.0K |
2014 | 375.0K | 162.0K | 86.0K | 71.0K |
2013 | 172.5K | 248.0K | 323.5K | 399.0K |
2012 | 0 | 0 | 0 | 97.0K |
2011 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 01, 2024 | kontulis caitlin | sold (taxes) | -320 | 0.958 | -335 | secretary & vp finance & admin |
Feb 26, 2024 | bitterman robert j | bought | 2,275 | 0.91 | 2,500 | president & ceo |
Feb 20, 2024 | bitterman robert j | sold (taxes) | -1,371 | 0.76 | -1,804 | president & ceo |
Feb 17, 2024 | kontulis caitlin | sold (taxes) | -345 | 0.66 | -523 | secretary & vp finance & admin |
Feb 15, 2024 | kontulis caitlin | sold (taxes) | -427 | 0.65 | -658 | secretary & vp finance & admin |
Oct 01, 2023 | bitterman robert j | sold (taxes) | -1,384 | 1.51 | -917 | president & ceo |
Jul 01, 2023 | bitterman robert j | bought | 2,840 | 2.84 | 1,000 | president & ceo |
Jun 30, 2023 | bitterman robert j | bought | 2,880 | 2.88 | 1,000 | president & ceo |
Jun 14, 2023 | ferrara robert l | bought | 6,200 | 3.1 | 2,000 | - |
Mar 01, 2023 | kontulis caitlin | sold (taxes) | -1,839 | 5.49 | -335 | secretary & vp finance & admin |
Which funds bought or sold PHIO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 24, 2024 | Cambridge Investment Research Advisors, Inc. | unchanged | - | -1,000 | 10,000 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | unchanged | - | -18,285 | 18,529 | -% |
Feb 26, 2024 | Virtu Financial LLC | new | - | 14,000 | 14,000 | -% |
Feb 14, 2024 | SABBY MANAGEMENT, LLC | added | 10.67 | -104,372,000 | 131,247,000 | 0.13% |
Feb 14, 2024 | Anson Funds Management LP | new | - | 119,643 | 119,643 | 0.01% |
Feb 14, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | -17,380 | 17,849 | -% |
Feb 14, 2024 | CITADEL ADVISORS LLC | new | - | 24,201 | 24,201 | -% |
Feb 13, 2024 | BlackRock Inc. | unchanged | - | -1.00 | 1.00 | -% |
Feb 13, 2024 | MORGAN STANLEY | unchanged | - | -94.00 | 95.00 | -% |
Unveiling Phio Pharmaceuticals Corp's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Phio Pharmaceuticals Corp)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.6B | 6.8B | -9.03 | 6.22 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.9B | 1.8B | -42.88 | 10.32 | ||||
BMRN | 15.8B | 2.5B | 76.99 | 6.4 | ||||
INCY | 11.9B | 3.8B | 15.95 | 3.16 | ||||
MID-CAP | ||||||||
APLS | 5.6B | 396.6M | -10.5 | 14 | ||||
BBIO | 4.8B | 107.9M | -7.27 | 60.35 | ||||
AXSM | 3.5B | 270.6M | -14.83 | 13.11 | ||||
ARWR | 2.9B | 240.7M | -9.66 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.81 | 3.87 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 25.07 | 4.5 | ||||
NVAX | 652.2M | 983.7M | -1.2 | 0.66 | ||||
CRBP | 390.9M | 881.7K | -8.76 | 466.16 | ||||
INO | 270.2M | 4.9M | -2 | 55.51 | ||||
IBIO | 6.4M | 2.1M | -0.24 | 2.14 |
Phio Pharmaceuticals Corp News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 | 2015Q1 | 2014Q4 | 2014Q3 | 2014Q2 | 2014Q1 |
Revenue | - | - | - | - | 21.00 | - | 57.00 | 58.00 | 23.00 | 12.00 | - | - | 9.00 | 10.00 | - | - | - | 34.00 | 14.00 | 16.00 | 12.00 | 29.00 |
Operating Expenses | 26.3% | 2,669 | 2,113 | 2,059 | 2,167 | 1,734 | 1,549 | 1,957 | 2,262 | - | - | - | - | - | - | - | - | - | - | - | - | - |
S&GA Expenses | 53.7% | 1,646 | 1,071 | 913 | 1,078 | 790 | 711 | 774 | 901 | - | - | - | - | - | - | - | - | - | - | - | - | - |
R&D Expenses | -1.8% | 1,023 | 1,042 | 1,146 | 1,089 | 944 | 838 | 1,183 | 1,361 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.00 |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | - | - | - | - | - | -1,727 | -1,493 | -1,901 | -2,239 | -2,002 | -2,339 | -2,212 | -2,212 | - | - | - | - | - | - | - | - | - |
Net Income | -27.0% | -2,660 | -2,094 | -2,035 | -2,119 | -1,727 | -1,493 | -1,901 | -2,239 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -1.8% | 9,364 | 9,539 | 12,296 | 9,707 | 12,814 | 15,791 | 20,144 | 22,162 | 25,170 | 27,943 | 31,657 | 33,856 | 15,739 | 18,239 | 20,211 | 14,305 | 8,039 | 10,079 | 12,108 | 13,678 | 15,322 |
Current Assets | -0.1% | 9,322 | 9,328 | 12,035 | 9,404 | 12,446 | 15,377 | 19,688 | 21,667 | 24,727 | 27,450 | 31,155 | 33,322 | 15,164 | 17,620 | 19,554 | 13,601 | 7,300 | 9,292 | 11,373 | 12,913 | 15,150 |
Cash Equivalents | 0.4% | 8,490 | 8,457 | 11,357 | 9,085 | 11,831 | 14,534 | 18,070 | 20,509 | 24,107 | 26,579 | 29,475 | 32,745 | 14,294 | 16,918 | 18,914 | 13,334 | 6,984 | 8,759 | 10,866 | 12,796 | 14,929 |
Net PPE | -95.8% | 6.00 | 142 | 157 | 167 | 183 | 198 | 206 | 215 | 133 | 153 | 142 | 145 | 157 | 173 | 183 | 202 | 210 | 231 | 152 | 155 | 172 |
Liabilities | -29.8% | 1,634 | 2,326 | 2,392 | 2,396 | 1,974 | 2,264 | 3,141 | 2,711 | 3,238 | 2,697 | 2,812 | 2,456 | 2,722 | 2,786 | 2,478 | 2,320 | 2,291 | 2,474 | 2,401 | 2,016 | 1,744 |
Current Liabilities | -29.8% | 1,634 | 2,326 | 2,392 | 2,396 | 1,939 | 2,194 | 3,037 | 2,573 | 3,068 | 2,495 | 2,578 | 2,191 | 2,196 | 2,230 | 1,893 | 1,937 | 1,880 | 2,036 | 1,936 | 1,516 | 1,744 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 231 | 231 | 231 | - | - | - | - | - | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | 231 | 231 | 231 | - | - | - | - | - | - |
Shareholder's Equity | 7.2% | 7,730 | 7,213 | 9,904 | 7,311 | 10,838 | 13,527 | 17,003 | 19,451 | 21,932 | 25,246 | 28,845 | 31,400 | 13,017 | 15,453 | 17,733 | 11,985 | 5,748 | 7,605 | 9,707 | 11,662 | 13,578 |
Retained Earnings | -1.4% | -139,206 | -137,311 | -134,531 | -131,982 | -128,380 | -125,649 | -122,073 | -119,542 | -116,900 | -113,449 | -109,707 | -107,020 | -103,613 | -101,151 | -98,842 | -97,170 | -94,819 | -92,159 | -90,065 | -88,030 | -85,911 |
Additional Paid-In Capital | 1.7% | 146,936 | 144,524 | 144,435 | 139,293 | 139,218 | 139,175 | 139,075 | 138,992 | 138,832 | 138,694 | 138,551 | 138,419 | 116,629 | 116,603 | 116,574 | 109,154 | 100,566 | 99,761 | 99,769 | 99,690 | 99,489 |
Accumulated Depreciation | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,122 | - | - | - | 1,048 | - | - | - | 981 |
Shares Outstanding | 62.4% | 3,747 | 2,307 | 1,985 | 1,151 | 1,139 | 1,136 | 1,138 | 1,130 | 1,128 | 1,128 | 1,128 | 890 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | - | 9,500 | - | - | - | 30,488 | - | - | - | 12,583 | - | - | - | 9,357 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 18.3% | -2,370 | -2,900 | -2,771 | -2,708 | -2,705 | -3,526 | -2,429 | -3,469 | -2,471 | -2,866 | -3,255 | -3,266 | -2,623 | -1,971 | -2,032 | -2,176 | -2,546 | -1,991 | -1,933 | -2,175 | -1,746 |
Share Based Compensation | -89.9% | 9.00 | 89.00 | 94.00 | 111 | 42.00 | 103 | 83.00 | 186 | 138 | 143 | 132 | 67.00 | 26.00 | 37.00 | 30.00 | 43.00 | 31.00 | 47.00 | 62.00 | 160 | 176 |
Cashflow From Investing | - | - | - | -5.00 | - | - | -7.00 | -10.00 | -104 | - | -30.00 | -15.00 | -6.00 | -1.00 | -8.00 | - | -10.00 | 5.00 | -61.00 | -15.00 | -1.00 | -5.00 |
Cashflow From Financing | - | 2,403 | - | 5,048 | -38.00 | 2.00 | -3.00 | - | -25.00 | -1.00 | - | - | 21,723 | - | -17.00 | 7,612 | 8,536 | 766 | -55.00 | 18.00 | 43.00 | 13,390 |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 6,332,000 | $ 7,012,000 |
General and administrative | 4,366,000 | 4,450,000 |
Loss on impairment of property and equipment | 126,000 | 0 |
Total operating expenses | 10,824,000 | 11,462,000 |
Operating loss | (10,824,000) | (11,462,000) |
Total other expense, net | (2,000) | (18,000) |
Net loss | $ (10,826,000) | $ (11,480,000) |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash | $ 8,490 | $ 11,781 |
Restricted cash | 0 | 50 |
Prepaid expenses and other current assets | 832 | 615 |
Total current assets | 9,322 | 12,446 |
Right of use asset | 33 | 161 |
Property and equipment, net | 6 | 183 |
Other assets | 3 | 24 |
Total assets | 9,364 | 12,814 |
Current liabilities: | ||
Accounts payable | 657 | 779 |
Accrued expenses | 942 | 1,025 |
Lease liability | 35 | 135 |
Total current liabilities | 1,634 | 1,939 |
Lease liability, net of current portion | 0 | 35 |
Total liabilities | 1,634 | 1,974 |
Commitments and contingencies (Footnote 7) | ||
Series D Preferred Stock, $0.0001 par value; 0 and 1 shares authorized, issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 0 | 2 |
Stockholders’ equity: | ||
Common stock, $0.0001 par value, 100,000,000 shares authorized; 3,747,329 and 1,139,024 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 0 | 0 |
Additional paid-in capital | 146,936 | 139,218 |
Accumulated deficit | (139,206) | (128,380) |
Total stockholders’ equity | 7,730 | 10,838 |
Total liabilities, preferred stock and stockholders’ equity | $ 9,364 | $ 12,814 |